<scp>PARP</scp> Inhibitors Rechallenge in Patients With Recurrent Ovarian Cancer: A Multicentre Real‐World Study in China
PARPi rechallenge as maintenance therapy may be feasible and tolerable. Achieving CR after the last chemotherapy is associated with longer PFS and combined therapies may improve outcomes, indicating potential to overcome PARPi resistance.
Authors
- Guorong Yao (ORCID: https://orcid.org/0000-0001-6856-1910)
- Jianxiao Zheng
- Jinghui Hu (ORCID: https://orcid.org/0000-0003-3048-6737)
- Fei Zheng (ORCID: https://orcid.org/0000-0002-0414-1914)
- Enchun Li (ORCID: https://orcid.org/0000-0003-3715-2430)
- Lingjun Zhao
- Jie Liu (ORCID: https://orcid.org/0000-0002-4530-1443)
- Feng Shao (ORCID: https://orcid.org/0000-0002-9587-5824)
- Shan Pan (ORCID: https://orcid.org/0000-0003-4702-6104)
- Jin Li (ORCID: https://orcid.org/0000-0001-8526-4395)
- Hua Zhu
- X. Wu (ORCID: https://orcid.org/0009-0003-9674-8389)
- Wei Zhou (ORCID: https://orcid.org/0000-0002-3139-989X)
Institutions
- Shanghai Medical College of Fudan University (CN)
- Wenzhou Medical University (CN)
- First Affiliated Hospital of Wenzhou Medical University (CN)
- Fudan University Shanghai Cancer Center (CN)
- Zhejiang Cancer Hospital (CN)
- Ningbo No. 2 Hospital (CN)
- Huzhou Central Hospital (CN)
- Women's Hospital, School of Medicine, Zhejiang University (CN)
- Zhejiang Taizhou Hospital (CN)
- Yueqing People's Hospital (CN)
- University of Chinese Academy of Sciences (CN)
- First Affiliated Hospital Zhejiang University (CN)
Publication Details
- Journal
- BJOG An International Journal of Obstetrics & Gynaecology
- Published
- 2025-04-24
- DOI
- https://doi.org/10.1111/1471-0528.18181
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00